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1. Introduction
Dendrimers are a relatively new class of synthetic,[1,2] highly
branched, nanospherical, and low dispersity macromolecules.[3,4]
They can be designed to provide quite a versatile choice of
external functional groups in order to reduce cytotoxicity and
enhance transepithelial transport,[5,6] and for interaction with
coupling molecules such as natural-based polymers[7] and fluo-
rescent probes,[8] and an inner hydrophobic core where other
molecules can be trapped.[6] Among the myriad possibilities,
dendrimers can find applications as delivery carriers of drugs[6,9]
and DNA (transfection),[10] imaging agents,[11,12] and as tissue
engineering scaffolding.[13] Although there are different routes
to synthesize dendrimers,[4] their maximum size is typically in
the order of !10–20 nm.[12,14] Moreover, it has also been
found[15] that high generation dendrimers (G7) with amine
capping-groups cause haemolysis and changes in red cell
morphology, and in general are overall cytotoxic. Therefore,
the strategy proposed herein envisions the surface engineering
of a dendrimer core grafted to natural-based and biocompa-
tible polymers (linear polymer chains) in order to obtain
copolymers of new architectures with tuned nanoparticle size
and more versatile macromolecules. These should make it
possible to avoid the cytotoxic effects of high-generation
dendrimers. This new class of material is expected to exhibit
entirely new properties since the structures might have sizes
larger than 10 nm and different surface properties (dendro-
nized polymer).[1] It is expected that the dendronized polymers
developed in the present work will have potential applications
as novel drug or gene delivery carriers for targeting certain
tissues or cell cultures. Such nanodevices could display a higher
loading capacity, and allow the bulk incorporation of bioactive
molecules of higher molecular weights and of different
chemistry, while maintaining high internalization and transfec-
tion efficiency as compared with conventional dendrimers.
In this study, novel water-soluble nanoparticles that consist
of a poly(amidoamine) (PAMAM) dendrimer core with
grafted carboxymethylchitosan (CMCht) chains (dendronized
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Novel highly branched biodegradable macromolecular systems have been developed by grafting carboxymethylchitosan
(CMCht) onto low generation poly(amidoamine) (PAMAM) dendrimers. Such structures organize into sphere-like nanopar-
ticles that are proposed to be used as carriers to deliver bioactive molecules aimed at controlling the behavior of stem cells,
namely their proliferation and differentiation. The nanoparticles did not exhibit significant cytotoxicity in the range of
concentrations below 1mg mL"1, and fluorescent probe labeled nanoparticles were found to be internalized with highly
efficiency by both human osteoblast-like cells and rat bone marrow stromal cells, under fluorescence-activated cell sorting and
fluorescencemicroscopy analyses. Dexamethasone (Dex) has been incorporated into CMCht/PAMAMdendrimer nanoparticles
and release rates were determined by high performance liquid chromatography. Moreover, the biochemical data demonstrates
that the Dex-loaded CMCht/PAMAM dendrimer nanoparticles promote the osteogenic differentiation of rat bone marrow
stromal cells, in vitro. The nanoparticles exhibit interesting physicochemical and biological properties and have great potential to
be used in fundamental cell biology studies as well as in a variety of biomedical applications, including tissue engineering and
regenerative medicine.









characterized and screened for cytotoxicity using a fibroblast-
cell line (L929) and rat bone marrow stromal cells (RBMSCs)
by means of performing a tetrazolium reduction (MTT) assay
and luminescent cell viability assay based on adenosine
triphosphate (ATP) quantification, respectively. The internali-
zation of fluorescein isothiocyanate (FITC)-labeled CMCht/
PAMAM dendrimer nanoparticles was also investigated using
both an osteoblastic cell line (SaOs-2) and RBMSCs as target
cells. These types of cells are widely used in tissue engineering
approaches[16,17] and are simple in-vitro systems for the
assessment of the internalization efficiency of fluorescen-
t-labeled molecules. It is our particular interest to engineer
these nanoparticles to find applications in the intracellular
controlled delivery of biological agents, including differentia-
tion factors or genetic material, to modulate stem cell behavior
while avoiding undesired secondary effects. In this context, the
capacity of dexamethasone-loaded CMCht/PAMAM nano-
particles to promote the osteogenic differentiation of RBMSCs
was also investigated. Alizarin red and alkaline phosphatase
(ALP) stainings were carried out to qualitatively assess the
mineralization capacity and ALP activity, which are known to
denote the osteogenic differentiation. The quantitative content
of ALP and osteocalcin, the early and late markers of
osteogenic differentiation, respectively, were also determined.
2. Results and Discussion
2.1. Characterization of the CMCht/PAMAM Dendrimer
Nanoparticles
Figure 1 shows FTIR spectra of the PAMAM-CT dendri-
mers, CMCht, and CMCht/PAMAMdendrimer nanoparticles.
The results suggest that CMCht was successfully synthesized,
as evidenced by the presence of characteristic absorption bands
of the carboxyl group at 1593 and 1420 cm"1 (nas COO
" and ns
COO"). The characterization of the molecular level conjugate
obtained by the coupling reaction of CMCht with the PAMAM
dendrimer was investigated by FTIR analysis. It was possible to
detect characteristic absorption bands of groups attributable to
both CMCht and the PAMAM dendrimer structure in the
CMCht/PAMAM dendrimer nanoparticles. There is an
increase in intensity of the bands at 1570 and 1200 cm"1
attributed to the amide II and C–N stretching vibrations, which
is evidence that substituted amines are present and that there is
possible chemical bonding between the CMCht and PAMAM.
The effective degree of conjugation, measured by 1H and 13C
NMR spectroscopy will be reported in a future work.
Some studies have shown that PAMAM is hydrolytically
degradable because of its amide skeleton, and hydrolysis
occurs slowly at physiological temperatures.[18] On the other
hand, chitosan and its derivatives have been shown to possess
bonds that are enzyme substrates.[19] Thus, the surface
engineering of dendrimers proposed herein may furnish
macromolecules with a different hydrolytic degradability,
andmay also release non-toxic products. As a consequence, the
nanoparticles may show entirely new drug-delivery profiles
and elimination rates. In preliminary degradation studies, a
decrease was observed in the intensity of the band at
1655–1630 cm"1, which corresponds to amide I (n C––O) of
the PAMAM dendrimer (see Supporting Information).
Decreases are also detected in the band at 1200 cm"1 that
corresponds to the C–N stretching vibration of the CMCht/
PAMAM dendrimer nanoparticles, and those at 1155 and
900 cm"1, attributed to the saccharine structure of CMCht. On
the other hand, increased intensities of peaks attributed to
the CH stretching bands and N–H stretching vibrations are
observed. These preliminary data support the idea that the
CMCht/PAMAM dendrimer nanoparticles are hydrolytically
degradable at physiological temperature and pH, due to
dissociation of their amide and glycosidic linkages. It has been
shown that the architecture of nanoparticles strongly dictate
the mechanisms and kinetics by which they are internalized by
cells.[20–21] Gao et al.[20] have recently demonstrated that the
optimal cellular uptake of particles by endocytosis occurs with
particles that have diameters of !50 nm. On the other hand,
the mechanism of internalization of particles with larger
diameters occurs preferentially by phagocytosis.[20] An atomic
force microscopy (AFM) image of the CMCht/PAMAM
nanoparticles is shown in Figure 2A. AFM characterization
clearly demonstrates that the synthesized macromolecules
consistently exhibit nanosphere-like shapes. It was also found
that the CMCht/PAMAM dendrimer nanoparticles could be
uniformly dispersed on a substrate by spreading a solution of
dendronized polymers on a freshly cleaved mica surface and
drying under a nitrogen gas stream.
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Figure 1. FTIR spectra of PAMAM G1.5, CMCht, and CMCht/PAMAM
dendrimer nanoparticles. (O) 3450 cm"1 corresponds to –OH group, (x)
2996–2882 cm"1 is attributed to CH stretching bands, (þ) 2860–2800 cm"1
corresponds to N–H stretching vibration, ($) 1655–1630 cm cm"1 corre-
sponds to Amide I (n C––O) (~) 1570 cm cm"1 corresponds to Amide II
(n C–N and dNH), (&) 1556 cm"1 is attributed to C–N stretching vibration
(C–N bond inside the core), (^) 1420 cm"1 corresponds to symmetric (s)
stretching mode of COO", (&) 1200 cm"1 corresponds to C–N stretching
vibration, and (f) 1155 and 900 cm"1 corresponds to saccharine structure.









The results of a morphometric analysis by AFM indicated
that the nanoparticles have an average diameter of 26 nm (dry
state) and average total area of !2123 nm2. These data were
corroborated by transmission electron microscopy (TEM)
observations. In Figure 2B,C it is possible to visualize the
CMCht/PAMAM dendrimer nanoparticles in greater detail. It
is also observed that the nanoparticles can form aggregates
(Fig. 2D).
CMCht with a degree of deacetylation (DA) of 80% and a
degree of substitution of 47% was used in the synthesis of the
CMCht/PAMAM nanoparticles. Chitosan with a high degree
of acetylation is insoluble in water because the acetylated units
can be involved in intramolecular hydrogen linkages, which in
part explains the insolubility of chitosan in water.[22]
Nevertheless, the modification of amino groups with
carboxylic groups allowed us to obtain CMCht, a water-soluble
chitosan derivate. Using potentiometric titrations it was
possible to verify that the precipitation of CMCht occurred
preferentially in a pH range from!2–6 (data not shown). Thus,
CMCht possesses protonated amino groups at pH 2, and
negative COO" ions at physiological pH. In other words, at
physiological pH the CMCht behaves as a weak polyanionic
polyelectrolyte, i.e., the amino groups are not protonated and
most of carboxy groups are not dissociated. Interactions
between non-covalent free carboxy groups of CMCht and/or
the PAMAM-CT dendrimer and amino groups of other
CMCht particles are possible, which may explain the formation
of nanoparticle aggregates. It is worth noting that Zhu et al.[23]
proposed the use of CMCht aggregates for the effective loading
and controlled release of drugs. On the other hand, during the
synthesis of CMCht/PAMAM dendrimer nanoparticles,
there are several binding points available onto which possible
cross-linking reactions may occur. This may also explain the
formation of nanoparticle aggregates. Nanoparticle aggrega-
tion might be prevented or minimized by optimizing the
concentrations of both CMCht and PAMAM.
Figure 3 shows the data obtained from the particle size
distribution analysis of the different nanoparticles in solution.
Figure 3A shows the low dispersivity of the PAMAM-CT (G
1.5) dendrimers used in the synthesis of the CMCht/PAMAM
dendrimer nanoparticles. These nanoparticles have a diameter
of 2% 1 nm, which is in agreement with previously reported
data.[24] After the synthesis of the CMCht/PAMAMdendrimer
nanoparticles, three kinds of particulate structures could be
detected with sizes of approximately 6% 2, 45% 15, and
250% 100 nm (Fig. 3B). The first peak has an intensity of
5.5% and should correspond to the modified dendrimer. The
second (36.2%) corresponds to the isolated CMCht/PAMAM
dendrimer nanoparticles, and the third (58.2%) to the
aggregated nanoparticles. Mammalian cells are sensitive to
the osmolality of the ambient medium, and variations of this
property may affect cell morphology and cell growth. It is
known that most cell culture mediums are produced to have a
osmolality in the range of 270–330mOsm kg"1, since these
values are acceptable for most cells.[25] In this study, Eagle’s
minimum essential medium (MEM) supplemented with fetal
bovine serum (FBS) and antibiotic-antimycotic (A/B, stan-
dard) with an osmolality of 310% 2 mOsm kg"1 was used. The
effect of the CMCht/PAMAM dendrimer nanoparticles on the
osmolality of the culture media was also investigated, since the
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Figure 2. Representative A) AFM and B–D) TEM images showing the
morphology of the CMCht/PAMAM dendrimer nanoparticles. A) The AFM
images show a uniform nanoparticle distribution, where it is also possible
to observe some aggregated nanoparticles. B) Low-magnification
TEM image of the CMCht/PAMAM dendrimer nanoparticles. C) High-
magnification TEM image of the CMCht/PAMAM dendrimer nanoparticles
(!40 nm). D) TEM image of aggregated CMCht/PAMAM dendrimer
nanoparticles (!250 nm).
Figure 3. Particle size distribution of A) PAMAM G 1.5 and B) CMCht/
PAMAM dendrimer nanoparticles.









addition of medium concentrates may increase the osmolality
of the media. The osmolality of the culture medium that
contained nanoparticles at a concentration ranging from 0.01
to 1mg mL"1 was assessed to be 315% 2 mOsm kg"1. Varying
the concentration of the CMCht/PAMAM dendrimer nano-
particles did not significantly change the osmolality of media,
which indicates that the cells are not cultured under osmotic
stress.
2.2. Cytotoxicity Screening
The cell viability in this work was preliminarily screened by
performing an MTT test, which is a quite reliable method for
assessing cytotoxicity.[26,27] A L929 fibroblast cell line was
exposed to different concentrations of CMCht/PAMAM den-
drimer nanoparticles over a period of 24 h (see Supporting
Information). Two polymers, water-soluble CMCht (linear
polymer) and PAMAM-CT G 1.5 (spherical polymer), were
selected for a comparative study considering the fact that
biocompatibility is thought to be influenced by various charac-
teristics including the polymer molecular weight, concentra-
tion, structure (linear, branched, cross-linked), surface charge
density, and flexibility.[26,28–30] Results indicate that dendro-
nized polymers at concentrations of 0.01 and 0.1mg mL"1 do
not induce any toxicity for the investigated culturing times.
However, at a concentration of 1mg mL"1, after 24 h the
viability of the L929 cells decreased in the presence of the
CMCht/PAMAM dendrimer nanoparticles, which suggests
moderate cytotoxic effects. These results agree with previous
studies where the concentration was reported to affect the
biocompatibility of polymers to a certain extent.[26,30] More-
over, our findings are also consistent with previous results which
indicated that high-molecular-weight structures may exhibit
more serious cytotoxic effects.[26] However, such trends are
meaningful only when the same type of polymer is compared.
Figure 4 shows the luminescent cell viability assay that was
carried out after culturing the RBMSCs in the presence of
different concentrations of CMCht/PAMAM dendrimer nano-
particles for 24 and 72 h. This assay is a homogeneous method
based on the quantification of ATP and thus is a more feasible
test for assessing the cytotoxicity of materials, since it signals
the presence of metabolically active cells. The luminescence
signal is proportional to the amount of ATP, which in turn is
directly proportional to the number of cells in the culture
medium. Statistically, it is possible to observe that increasing
concentrations of CMCht/PAMAM dendrimer nanoparticles
did not affect the viability (ATP content) of RBMSCs after
24 h (P> 0.05). When culturing the RBMSCs in MEM and in
the presence of CMCht/PAMAM dendrimer nanoparticles, a
statistical increase in viability was observed from 24 to 72 h
(P< 0.0001). A statistical difference on the viability of RBMSCs
was not seen when culturing RBMSCs in the presence of MEM
and CMCht/PAMAM dendrimer nanoparticles in the range of
concentrations between 0.01 and 0.1mg mL"1 after 72 h
(P> 0.05). However, the viability of RBMSCs decreased by
8.5% when culturing in the presence of 1mg mL"1 of CMCht/
PAMAM dendrimer nanoparticles (P< 0.05) as compared
with the control. The latex extracts (positive control) have
shown a high cytotoxic effect over RBMSCs, as seen by the low
luminescence values after 24 and 72 h. These results demon-
strate that RBMSCs remain viable in the presence of CMCht/
PAMAM dendrimer nanoparticles at concentrations <1mg
mL"1. Similar data were observed for the viability of L929
cells, which provides further evidence of the low cytotoxic
effects of the CMCht/PAMAMdendrimer nanoparticles in the
range of concentrations <1mg mL"1.
2.3. Internalization Efficiency of the CMCht/PAMAM
Dendrimer Nanoparticles
Several studies [5,9,31,32] have been performed to clarify the
entry and retention mechanisms of nanoparticles on mamma-
lian cells as well as to investigate cell death.[33] For instance, it
has been reported[5] that the cationic surface charge of particles
is responsible for their interactions with the anionic glycopro-
teins and phospholipids of the cell membrane surface, which
possibly facilitates their internalization. In the present case, it is
expected that these types of interactions are responsible for the
entry of CMCht/PAMAM dendrimer nanoparticles into the
cell cytosol, either by passive transport caused through pertur-
bations of themembrane or by endocytosis.[5] After being trap-
ped within the endosome, the nanoparticles must be released
into the cytosol before being subjected to acidic and/or
enzymatic degradation. Nevertheless, because of the presence
of protonated residues in the chain of the CMCht, which has a
buffer capacity, it is expected that these nanoparticles can
retard the degradation caused by acidification or enzymatic
degradation within the endosomes. Theoretically, when loaded
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Figure 4. Viable RBMSCs after incubation in a culture medium with
different concentrations of CMCht/PAMAM dendrimer nanoparticles for
the period of 24 and 72 h. The cell number correlates with luminescence.
A) MEM (negative control), B) 0.01, C) 0.1, and D) 1.0mgmL"1 of CMCht/
PAMAM dendrimer nanoparticles, and E) MEM that contained an latex
extract (positive control) (p< 0.0001). Results expressed as an avera-
ge% standard deviation, n¼ 12. (Data were examined at a level of signifi-
cance of p< 0.05.)









with drugs or DNA, this type of nanocarrier may increase the
availability of drugs inside the cells or the transfection
efficiency. In this study, the internalization and intracellular
end-condition of the CMCht/PAMAM dendrimer nanoparti-
cles were investigated by grafting a fluorescent label probe
(FITC). This study was firstly performed using a SaOs-2 cell
line and later on RBMSCs. Figure 5 shows the fluorescence
microscopy images of SaOs-2 cells cultured in the presence of
FITC-labeled CMCht/PAMAM dendrimer nanoparticles. The
nanoparticles tested in this experiment consisted of the fraction
of the total with size <220 nm, which was easily obtained by a
filtration technique. It is apparent that CMCht/PAMAM
dendrimer nanoparticles (green) are only present at the SaOs-2
cell membrane walls in low numbers after 3 h (white arrows),
but in increasing amounts after a period of 12 h (Fig. 5A,B).
However, after 24 h it is clearly seen that the CMCht/PAMAM
dendrimer nanoparticles are internalized and widely distrib-
uted in the cytoplasm of the SaOs-2 cells (Fig. 5C). Moreover,
there is also evidence of the presence of nanoparticles in the
cell nuclei, as observed by the colocalization of the nuclei
marker (blue) and FITC fluorescence (green). Cells continued
to internalize the CMCht/PAMAM dendrimer nanoparticles
(higher fluorescent signals) when cultured for longer periods of
time, thus retaining their proliferation rate and remaining
viable (Fig. 5D). A typical feature of apoptosis is the presence
of chromatin condensation and nuclear fragmentation.[28]
Apoptosis can be detected by nuclear morphology after
staining with 4,6-diamidino-2-phenylindole dilactate (DAPI)
blue or Hoechst 33258, for example. In Figure 5C,D, it is
seen that SaOs-2 cells exhibit normal sized and round
nuclei with homogeneous chromatin. Microscopic obser-
vations during the course of cell culturing in the presence
of FITC-labeled CMCht/PAMAM dendrimer nanopar-
ticles showed no morphological changes or cellular
senescence, which is a good indication of cell survival.
On the other hand, significant cell death was detected
after 24 h for a culture of SaOs-2 cells in a media that
contained FITC (control). These results also highlight
the fact that the FITC-labeled CMCht/PAMAM den-
drimer nanoparticles are quite stable, since their
fluorescence was maintained over a period of 14 d.
The fact that internalization of the nanoparticles was not
well observed after 3 h can be attributed to the rather
high detection limit of the fluorescence microscope.
Fluorescent activated cell sorting (FACS) analysis was
performed towards circumventing this limitation. In this
analysis, primary cultures and FITC-labeled CMCht/
PAMAM dendrimer nanoparticles at a concentration of
0.01mg mL"1 were used. This concentration is impos-
sible to detect by fluorescence microscopy and, there-
fore, makes a good test case for FACS.
Figure 6 shows the results of FACS analysis after
culturing the RBMSCs in the presence of the FITC-
labeled CMCht/PAMAM dendrimer nanoparticles for
times up to 14 d. Flow-cytometry studies revealed
increasing levels of fluorescence associated with cells
after incubation of RBMSCs with CMCht/PAMAM dendri-
mer nanoparticles for the period of 12 h to 7 d. The present data
show that nanoparticles were internalized with high efficiency
by RBMSCs. The fraction of RBMSCs that internalized the
nanoparticles reached 50.3% after 12 h and a maximum of
95.7% after 7 d of culturing (Table 1). At day 14, a decrease of
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Figure 5. Fluorescence microscopy images of SaOs-2 cells after culturing in the
presence of FITC-labeled CMCht/PAMAM dendrimer nanoparticles 1mg mL"1
(green) for: A) 3 h, B) 12 h, C) 24 h, and D) 14 d. Nuclear DNA was labeled with
DAPI (blue).
Figure 6. FACS data of live RBMSCs (% gated) after culturing in: MEM
medium (light-grey peaks, control) and MEM medium with FITC-labeled
dendrimer CMCht /PAMAMnanoparticles 0.01mgmL"1 (dark-grey peaks)
for the period of 12 h, 24 h, 7 d, and 14 d.









the internalization was detected, which may be related to the
fact that RBMSCs reach confluence around day 7. Moreover,
the RBMSCs were stained with propidium iodide (PI) to
quantify the fraction of live cells.
From Table 1, it is concluded that the fraction of live cells
cultured in the presence of FITC-labeled CMCht/PAMAM
dendrimer nanoparticles did not significantly differ from that
of the control. This result also demonstrates the biocompatible
nature of the FITC-labeled CMCht/PAMAM dendrimer
nanoparticles.
Fluorescence microscopy of RBMSCs cultured in the
presence of FITC-labeled CMCht/PAMAM dendrimer nano-
particles corroborated the above-mentioned results of inter-
nalization studies carried out using a cell line, i.e., it confirmed
that the nanoparticles were internalized and widely distributed
in the cytoplasm of RBMSCs (Fig. 7). RBMSCs continued to
internalize the nanoparticles (higher fluorescent signals) when
cultured for longer periods of time. In addition, RBMSCs were
also stained with Texas-red phalloidin for observation of
the cell cytoskeletons. This makes it possible to assess whether
the presence of the FITC-labeled CMCht/PAMAMdendrimer
nanoparticles affects the cytoskeleton. It is known that cell
mutations involve rearrangements and morphological mod-
ifications.[34] From careful examination it was concluded that
no morphological changes could be detected compared with
the control (data not shown). Interestingly, it appears that the
FITC-labeled CMCht/PAMAM dendrimer nanoparticles are
confined inside vesicular bodies that resemble endosomes. This
observation would support the idea that their transport may
occur through an endocytotic transcellular pathway. As was
also observed for SaOS-2 cells, there is evidence of the
presence of nanoparticles in the RBMSCs nucleus.
2.4. Mechanism of CMCht/PAMAM Dendrimer
Nanoparticles Internalization
In order to gain further insight into the internalization
mechanism, complementary experiments were carried out.
The in-vitro experimental design consisted of culturing the
RBMSCs in the presence of FITC-labeled CMCht/PAMAM
nanoparticles and restrictive endocytotic drugs such as
colchicine.[5] It is known that colchicine binds tightly to
microtubules to cause microtubule depolymerization, and by
this mechanism affects endocytosis.
On the other hand, it has been report-
ed[35,36] that the translocation of macro-
molecules larger than 10 nm from the
cytoplasm to the nucleus is by active
transport through the nuclear pore com-
plex (NPC), whereas small molecules and
proteins smaller than 20–40 kDa cross the
10 nm diameter channels of the NPC by
passive diffusion. Thus, we also exposed
the RBMSCs to apyrase, a nuclear trans-
locator inhibitor that causes ATP deple-
tion, to study whether this treatment
affects translocation of the FITC-labeled
CMCht/PAMAM nanoparticles from the
cytoplasm to the nucleus.
Figure 8 shows the percentage of
RBMSC-associated fluorescence as a
result of nanoparticle internalization after
culturing the cells in the presence and/or
absence of the restrictive drugs, for
periods of 12 h, 24 h, 7 d, and 14 d.
The results show that when culturing
the RBMSCs in the presence of colchicine
(green peak), apyrase (dark-blue peak),
or exposed to both (red peak), a decrease
in nanoparticle internalization is always
observed. In fact, when colchicine is not
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Figure 7. Fluorescence microscopy images of the RBMSCs cultured in the presence of FITC-labeled
CMCht/PAMAM dendrimer nanoparticles 0.1mg mL"1 (green) for: A) 12 h, B) 24 h, C) 7 d, and D)
14 d. Nuclear DNA and cytoskeleton were labeled with Hoechst 33258 (blue) and Texas-Red
phalloidin (red), respectively.
Table 1. FACS data of the percentage of internalization of FITC-labeled
CMCht/PAMAM dendrimer nanoparticles by the fraction of live RBMSCs.
The percentage of live cells (stained with PI) was obtained from the analysis







12 h 24 h 7 d 14 d 12 h 24 h 7 d 14 d
FITC-labeled CMCht/
PAMAM nanoparticles
50.3 70.1 95.7 89.3 96.0 93.7 75.4 62.6
MEM medium (control) 0.4 0.6 0.3 0.5 87.6 92.9 81.8 53.9









present in the culture medium the nanoparticle internalization
efficiency doubles for the culturing periods comprised of the
first 24 h. However, the difference is not so pronounced after
7 and 14 d. Therefore, the present studies support the idea that
not only nanoparticle internalization is highly dependent on
the endocytosis mechanism, but also suggest that the nano-
particles enter the cells by a mechanism that might not be
exclusively endocytotic. As previously discussed, the size of the
nanoparticles strongly dictates the mechanism by which they
are internalized.[20,37] The nanoparticles described herein have
sizes that range from approximately 6 to 220 nm, and thus may
be internalized by different mechanisms, i.e., cellular uptake of
particles either by passive transport caused through perturba-
tions of the membrane, endocytosis, and phagocytosis.[5,20]
On the other hand, FACS analysis showed that apyrase
exposure did not affect nanoparticle internalization to a great
extent after 7 and 14 d. However, after 24 h the observed inter-
nalization values with apyrase exposure (dark-blue peak) are
significantly lower when compared with those of nanoparticle
internalization without apyrase exposure (black peaks).
RBMSCs exposed to the restrictive
drugs were also observed by fluorescence
microscopy (Fig. 9).As shown in Figure 9C,
it was observed that the FITC-labeled
CMCht/PAMAM dendrimer nanoparti-
cles were internalized and widely distrib-
uted in the cytoplasm of the RBMSCs,
and the cells exhibited a normal morphol-
ogy after 14 d. On the other hand, the
depletion of ATP in the cells exposed to
apyrase resulted in a decrease in nano-
particle internalization, which is more
evident under fluorescence microscopy
observation than by FACS analysis
(Fig. 9D). A preferential localization
around the perinuclear area was observed
when the cells were treated with apyrase.
It should be noted that the cells were not
exposed to permeabilizing agents to avoid
any undesired effects on the integrity of
the cell nuclei. This result suggests that
the presence of apyrase also prevents the
nanocarriers from entering the cell nuclei,
at least to a certain extent, since small
molecules cross the 10 nm diameter
channels of the NPC by passive diffusion.
However, further complimentary studies
are needed to clearly elucidate the
possible localization of nanoparticles in
the nucleus and whether nuclear import is
an energy-dependent active process, since
noATP and/or GTP regenerating systems
or temperature-dependent assays were
carried out.[35,36] On the other hand, when
colchicine was present in the culture
medium a dramatic decrease in nanopar-
ticle internalization was observed (Figs. 9E,F). In other words,
the presence of colchicine restricted nanoparticle interna-
lization. In addition, the exposure of RBMSCs to colchicine
seems to prevent the formation of vesicular structures, as
evidenced by the observation of uniform fluorescence of the
FITC-labeled CMCht/PAMAM dendrimer nanoparticles
around the perinuclear area. This assay further suggests that
nanoparticles enter the cells by a mechanism that is not
exclusively endocytotic. The colchicine treatment negatively
affected cell growth, i.e., only a small number of stained nuclei
were observed. The cytoskeleton morphology (Figs. B, E, and
F) is also altered as evidenced by the increase in length of actin
filaments when compared to that of the control (Fig. 9A). This
is not surprising, since it is well known that colchicine disrupts
the cytoskeleton.[38] Tsai et al.[39] reported that colchicine at
concentrations less than 1' 10"6 M caused disruption of
microtubular structures of neutrophiles, but had little effect on
either F-actin or on cellular mechanical properties. On the
other hand, higher concentrations of colchicine disrupted the
microtubular structure, but also caused increased actin
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Figure 8. FACS data of RBMCS-associated fluorescence (% gated) after culturing in different culture
media for 12 h, 24 h, 7 d, and 14 d. MEM (yellow). MEM with 0.1U mL"1 apyrase and 1' 10"6 M
colchicine (light-blue). MEM that contained 0.01mg mL"1 of FITC-labeled CMCht/PAMAM den-
drimer nanoparticles and 1' 10"6 M colchicine (green). MEM that contained 0.01mg mL"1 of
FITC-labeled CMCht/PAMAM dendrimer nanoparticles, 1' 10"6 M colchicine, and 0.1U mL"1
apyrase (red). MEM that contained 0.01mg mL"1 of FITC-labeled CMCht /PAMAM dendrimer
nanoparticles and 0.1U mL"1 apyrase (dark-blue). MEM that contained 0.01mg mL"1 FITC-labeled
CMCht/PAMAM dendrimer nanoparticles (black).









polymerization and cell rigidity. Thus, the present data
demonstrate that the CMCht/PAMAM dendrimer nanopar-
ticles have great potential for various applications as
intracellular nanocarriers since they show properties useful
for launching cell-impermeable drugs/DNAwithin target cells,
for example. Moreover, in addition to their applications in
intracellular drug-delivery systems, they can also be used for
live-cell imaging during in-vitro culturing. It is further
emphasized that the low toxicity of the CMCht/PAMAM
nanoparticles is in contrast to those of most transfection agents
and fluorescent labels, which exhibit
significant cytotoxicity and have a period
of use limited to only a few hours.[31,40]
By means of optimizing parameters
such as the size and surface chemistry of
the nanoparticles, we expect to develop
more stable and versatile intracellular
nanocarriers aimed at maximizing the
drug availability to damaged tissues and
decreasing the overall drug dosage and
the need for frequent re-dosage, while
simultaneously preventing drug exposure
to healthy tissues.
2.5. In-Vitro Release of
Dexamethasone from CMCht/
PAMAM Dendrimer Nanoparticles
Glucocorticoids such as dexamethasone
(Dex) have been shown[41–43] to promote
the osteogenic differentiation of stem
cells. On the other hand, glucocorticoids
bind to the cytoplasmatic glucocorticoid
receptor.[44,45] Therefore, Dex is an ideal
drug to further investigate the loading and
performance of the CMCht/PAMAM
dendrimer nanoparticles as an intracellu-
lar drug-delivery system. Figure 10 depicts
the Dex release profile from CMCht/
PAMAM dendrimer nanoparticles at
physiological pH. We have studied the
effect of serum proteins on the retention
of Dex by adding 15%FBS to a phosphate
buffered saline (PBS) solution. An initial
burst release of Dex is observed and the
concentration reaches a maximum of 4mg
mL"1 in PBS with 15% FBS after 24 h.
The release kinetics of Dex followed a
steady release after the initial burst, which
lasted for 7 d. This data shows that Dex is
released as the free drug. The release of
Dex from nanoparticles seems to be very
slow for about 6 d after the initial release
period, in the presence of serum proteins.
By comparing the release rate of Dex in
the absence of serum proteins, it can be seen that Dex is
released more slowly after the initial burst period and a higher
amount of Dex is still being released during this second stage.
This data shows that the presence of serum proteins increases
the initial amount of Dex released from the nanoparticles. This
data is in agreement with a previous study,[46] and may be
related to nanoparticle degradation by serum proteins. Despite
this, further degradation studies need to be carried out to
elucidate this issue. The timescale for the Dex release from the
nanoparticles is of the same order of their internalization by
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Figure 9. Fluorescence microscopy images of the RBMSCs cultured in different culture medium,
after 14 d: A) MEM. B) MEM with 0.1U mL"1 apyrase and 1' 10"6 M colchicine. C) MEM with
0.1mg mL"1 of FITC-labeled CMCht/PAMAM dendrimer nanoparticles. D) MEM with 0.1U mL"1
apyrase and 0.1mg mL"1 of FITC-labeled CMCht/PAMAM dendrimer nanoparticles. E) MEM
medium with 1' 10"6 M colchicine and 0.1mg mL"1 of FITC-labeled CMCht/PAMAM dendrimer
nanoparticles. F) MEMmedium with 1' 10"6 M colchicine, 0.1UmL"1 apyrase, and 0.1mgmL"1 of
FITC-labeled CMCht/PAMAM dendrimer nanoparticles. FITC-labeled CMCht /PAMAM dendrimer
nanoparticles (green). Nuclear DNA and cytoskeleton were labeled with Hoechst 33258 (blue) and
Texas-Red phalloidin (red), respectively.









cells. This could provide an indication of the retention of Dex
within the nanoparticles in culture media and its release rate
after it has been internalized by cells, in vitro. This and other
issues, such as what will be the Dex release profile inside the
endosomes (pH 5) and in in-vivo situations, remains to be
examined in future studies.
2.6. In-Vitro Osteogenic
Differentiation of RBMSCs Exposed
to the CMCht/PAMAM Dendrimer
Nanoparticles
An osteodifferentiation study is an
interesting in-vitro model to validate the
incorporation and release of Dex from the
nanocarriers, since osteogenic differentia-
tion varies with the dose and duration of
exposure to the glucocorticoids.[41] On the
other hand, in-vitro osteogenic differen-
tiation of stem cells mimics many char-
acteristics of the normal osteogenesis that
occur in vivo. Under appropriate culture
conditions, stem cells are induced to
express osteogenic markers such as bone-
specific ALP, osteopontin, and osteocal-
cin.[42,47] The deposition of an extracel-
lular matrix, namely type I collagen, may
occur, and as a consequence mineraliza-
tion can be observed.[43,48,49] The presence
of calcium is a late marker of osteoblast
differentiation. In this work, the miner-
alization was qualitatively investigated using
Alizarin red staining (Fig. 11). These
results have shown that RBMSC cultures
exposed to Dex-loaded CMCht/PAMAM dendrimer nano-
particles show high mineralization, as seen by the calcium
staining (Figs. 11C,D). The extent of calcium deposition in
cultures exposed to Dex-loaded CMCht/PAMAM dendrimer
nanoparticles at a final concentration of 0.01mg mL"1 was of
the samemagnitude as in cultures treated with standard culture
media with Dex (osteogenic media), while RBMSCs cultured
in the presence of CMCht/PAMAM dendrimer nanoparticles
showed no mineralized nodules (Fig. 11B). This is an
important result since it shows that incorporation of Dex
and the nanoparticle concentration may influence the intensity
and extent of mineralization. Moreover, an overall increase of
calcium deposition in cultures exposed to Dex can be seen
compared with those lacking the glucocorticoid (Figs. 11A, B,
and F). The in-vitro release studies showed that the Dex
concentration reaches a maximum of 4mg mL"1 in PBS with
15% FBS after 24 h. Therefore, in a culture media with 0.01mg
mL"1 of Dex-loaded CMCht/PAMAM dendrimer nanoparti-
cles, the concentration of Dex is expected to be in the
magnitude of 40 ng mL"1 (10' 10"9 M). Therefore, the Dex
released from the CMCht/PAMAM dendrimer nanoparticles
resembles that from osteogenic media. This range of
concentrations of Dex has been shown to be effective for
the osteogenic differentiation of MSCs.[41,50]
It is known that ALP, a cell surface glycoprotein, is an early
marker of osteogenic differentiation.[47,51] To confirm the
osteogenic differentiation of RBMSCs exposed to Dex-loaded
CMCht/PAMAM dendrimer nanoparticles, we carried out an
ALP staining (Fig. 12). As seen for calcium staining, the
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Figure 10. Dex release from 1mg mL"1 of CMCht/PAMAM dendrimer
nanoparticles at pH 7.4 (PBS buffer) in the presence (-*-) or absence
(-&-) of 15% FBS under agitation at 37 8C, at 60 rpm, and determined by
high performance liquid chromatography for periods between 1 h and 7 d.
The results are expressed as an average% standard deviation, n¼ 6.
Figure 11. Calcium staining (Alizarin red) of RBMSCs after culturing in different culture medium for
the period of 14 d. A) MEM (negative control). B) CMCht/PAMAM dendrimer nanoparticles (1mg
mL"1). C) Dex-loaded CMCht/PAMAM dendrimer nanoparticles (1mg mL"1). D) Dex-loaded
CMCht/PAMAM dendrimer nanoparticles (0.01mg mL"1). E) Osteogenic medium and F) MEM
with b-glycerophosphate. (Original magnification: '100, bar: 5mm.)









presence of cuboid-shaped clusters stained with ALP is higher
in cultures exposed to Dex-loaded CMCht/PAMAM dendri-
mer nanoparticles (Figs. 12C,D). It is possible to observe a
strong ALP staining in cultures with Dex-loaded CMCht/
PAMAM nanoparticles at a concentration of 0.01mg mL"1.
These results are further corroborated by the above miner-
alization data, which suggest that osteogenic differentiation of
RBMSCs occurs in the presence of Dex-loaded CMCht/
PAMAM dendrimer nanoparticles.
Figure 13 shows the quantitative analysis of ALP activity,
both normalized for DNA content (left) and non-normalized
(right). Cultures grown in the presence of standard medium,
CMCht/PAMAM dendrimer nanoparti-
cles, and b-glycerophosphate presented
similar ALP activity. It can be seen that
ALP activity is increased in cultures with
Dex-loaded CMCht/PAMAM dendrimer
nanoparticles. No statistical differences
were observed for cultures grown in the
presence of osteogenic medium and
standard culture media with different
concentrations of Dex-loaded CMCht/
PAMAM dendrimer nanoparticles. As
expected, we observed the up-regulation
of ALP in the RBMSCs exposed to Dex.
Dex consistently increased ALP activity,
but it should be noted that Dex does not
globally stimulate all genes considered to
be part of osteoblast differentiation. On
the other hand, the Dex actions are
somehow species specific, or dependent
on the culture conditions.[49]
The late osteogenic marker and bone-
specific osteocalcin was also measured by
performing an enzyme-linked immuno-
sorbent assay (ELISA, Fig. 14). It is
possible to observe that osteocalcin
deposition occurs in cultures exposed to
the Dex-loaded CMCht/PAMAM den-
drimer nanoparticles.
In addition, higher osteocalcin content in cultures treated
with osteogenic media can be seen. Despite this, the magnitude
of osteocalcin deposition does not present significant differ-
ences when compared to that of cultures with 0.01mg mL"1
Dex-loaded CMCht/PAMAMdendrimer nanoparticles. These
observations can be explained by the fact that differentiation
proceeds mineralization and the responsiveness of osteocalcin
synthesis to long-term exposure to Dex, as this late marker
appears to reach a maximum just before or during mineralized
tissue formation.[52] Therefore, the present biochemical
findings demonstrate that RBMSCs differentiate into osteo-
blasts and organize into a mineralized matrix when cultured in
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Figure 12. ALP staining of the RBMSCs cultured in different culture medium for the period of 14 d.
A) MEM (negative control). B) CMCht/PAMAM dendrimer nanoparticles (1mg mL"1). C) Dex-
loaded CMCht/PAMAM dendrimer nanoparticles (1mg mL"1). D) Dex-loaded CMCht/PAMAM
dendrimer nanoparticles (0.01mg mL"1). E) Osteogenic medium and F) MEM with b-glycero-
phosphate. (Original magnification: '100, bar: 5mm.)
Figure 13. ALP activity (left) and ALP activity per DNA content (right) of RBMSCs cultured in the presence of different culture medium after 14 d. A) MEM
(negative control). B) CMCht/PAMAM dendrimer nanoparticles (1mg mL"1). C) Dex-loaded CMCht/PAMAM dendrimer nanoparticles (1mg mL"1).
D) Dex-loaded CMCht/PAMAM dendrimer nanoparticles (0.01mg mL"1). E) Osteogenic medium and F) MEM with b-glycerophosphate. Results
expressed as an average% standard deviation, n¼ 12.









the presence of Dex-loaded CMCht/PAMAM dendrimer
nanoparticles.
While the intracellular Dex release profile is yet to be
determined, the in-vitro release and differentiation studies
have proved particularly useful to demonstrate that Dex was
incorporated into the CMCht/PAMAM dendrimer nanopar-
ticles and was released at a concentration that caused no
negative effects on the RBMSCs osteogenic differentiation.
3. Conclusions
The results in this paper demonstrate that a combination of
synthetic and natural-based polymers enables the preparation
of CMCht/PAMAM dendrimer nanoparticles of suitable
diameters to cover a wide range of intracellular delivery appli-
cations. In-vitro tests showed that the CMCht/PAMAM den-
drimer nanoparticles do not exert any significant cytotoxic
effect over both L929 fibroblast and RBMSCs for concentra-
tions below 1mg mL"1.
Furthermore, the successful internalization of the nanopar-
ticles by two different types of cells, i.e., cell lines and primary
cultures, was also demonstrated. The biochemical data pre-
sented herein also proved that theDex-loadedCMCht/PAMAM
dendrimer nanoparticles induced the osteogenic differentia-
tion of rat bonemarrow stem cells in vitro. Therefore, the novel
CMCht/PAMAM dendrimer nanoparticles may be used as
targeted drug-delivery carriers to cover a wide range of
applications that involve the efficient intracellular delivery of
biological agents to modulate the behavior of cells. These
might include the use of differentiation factors to act from the
inside of the cell or on genetic material. The incorporation of
fluorescent labels for live-cell imaging and monitoring of the
final intracellular fate of such structures is also possible.
4. Experimental
Synthesis of the CMCht/PAMAM nanoparticles: CMCht with a
degree of deacetylation of 80% and degree of substitution of 47% was
synthesized by a chemical modification route of chitin (Sigma,
Germany) as described by Chen et al. [53]. Starburst PAMAM-
carboxylic acid terminated dendrimers, PAMAM-CT (generation 1.5,
20% (w/v) methanolic solution) with an ethylenediamine core were
purchased from Aldrich. CMCht/PAMAM dendrimer nanoparticles
were prepared in a stepwise manner as follows: i) increasing the
generation of the PAMAM-CT (G 1.5), ii) obtaining a PAMAM-
methyl ester terminated dendrimer, iii) reaction of PAMAM and
CMCht (the reaction occurs by a condensation reaction between the
methyl ester and amine groups [54]), and iv) converting the methyl
ester groups that do not react into carboxylic groups in the CMCht/
PAMAM dendrimer, followed by precipitation. First, the increase of
the dendrimers’ generation was carried out as follows: an appropriate
volume of PAMAM-CT (G 1.5) in methanol was transferred to a 2mL
volumetric flask and the solvent evaporated off under nitrogen gas, and
the traces dried under vacuum in order to completely remove the
methanol. The starting compound was re-dissolved in ultra-pure water
to give a final concentration of 10mg mL"1 and the pH was adjusted to
6.5 with dilute hydrochloric acid solution (Riedel de-Haen, Germany).
1-Ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDC,
Fluka, Slovakia) was then added to the solution at a molar ratio
sufficient to modify the carboxylate residue of the dendrimers, and the
solution was kept under agitation for 30min at room temperature.
Ethylenediamine (EDA, Sigma, Germany) was added to the solution
at a molar ratio equal to that of EDC and left to react for at least 4 h.
After this period the excess EDC was removed by dialysis (cellulose
tubing, benzoylated for separating compounds with a molecular weight
of (1200 from compounds with a molecular weight >2000, Sigma,
Germany). The compound was used without purification in the next
step. After preparing the PAMAM-amine terminated compound
(PAMAM-AT) an exhaustive alkylation of the primary amines
(Michael addition) was performed [55]. An appropriate volume of
PAMAM-AT (!8.4mmol) was transferred to a 50mL flask and 30mL
of methanol (Sigma, Germany) and 1.14mL of methyl methacrylate
(!12.6mmol, Fluka, Germany) were added. The solution was kept
under agitation in a water bath for 24 h at 50 8C, to obtain the
PAMAM-methyl ester. The CMCht (100mg) dissolved in ultrapure
water (10mL) was mixed with the PAMAM-methyl ester dendrimer
(50mg), whichwas previously dissolved in a 20/80 water/methanol (v/v)
solution. The final solution was diluted by adding 30mL of methanol
and kept under agitation for 72 h. After this period, a CMCht/PAMAM
dendrimers with carboxylic-terminated groups were obtained as
described elsewhere [54]. CMCht/PAMAM dendrimer nanoparticles
were then precipitated after addition of an appropriate volume of a
saturated Na2CO3 (Aldrich, Germany) solution and acetone (Prona-
lab, Portugal). Some CMCht/PAMAM dendrimer nanoparticles were
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Figure 14. Osteocalcin quantification (left) and osteocalcin per DNA content (right) of RBMSCs cultured in the presence of different culture medium after
14 d. A) MEM (negative control). B) CMCht/PAMAM dendrimer nanoparticles (1mg mL"1). C) Dex-loaded CMCht/PAMAM dendrimer nanoparticles
(1mg mL"1). D) Dex-loaded CMCht/PAMAM dendrimer nanoparticles (0.01mg mL"1). E) Osteogenic medium and F) MEM with b-glycerophosphate.
Results expressed as an average% standard deviation, n¼ 12.









mixed with a Dex solution with a final concentration of 5' 10"4 M
under agitation (w/w). The mixture was then added to the precipitation
media that consisted of a saturated Na2CO3 and acetone solution,
under vigorous agitation. Precipitates were collected by filtration and
dispersed in ultrapure water for dialysis over a period of 48 h. Both
CMCht/PAMAM and Dex-loaded CMCht/PAMAM dendrimer
nanoparticles were obtained by freezing the solution at "80 8C and
freeze-drying (Telstar-Cryodos-80, Spain) up to 4 d to completely
remove the solvent. It is worth noting that the CMCht/PAMAM
dendrimer nanoparticles were water-soluble at physiological pH.
Labeling of CMCht/PAMAM Dendrimer Nanoparticles with
FITC: A 10mg mL"1 FITC (Sigma, Germany) solution was prepared
in anhydrous dimethyl sulfoxide (DMSO, Riedel de-Haen) (dark
conditions). Conjugates of CMCht/PAMAM-FITC were prepared by
covalently bonding the amine group of CMCht and the isothyocianate
group of FITC (thiourea bond). First, a 10mg mL"1 CMCht/PAMAM
dendrimer nanoparticle solution was prepared in a carbonate-
bicarbonate coupled buffer of pH 9.2. A 50mL aliquot of the FITC/
DMSO solution was then added for each milliliter of the CMCht/
PAMAM dendrimer nanoparticle buffered solution under agitation,
and the mixture was kept in the dark at 4 8C for 8 h. The FITC-labeled
CMCht/PAMAM dendrimer nanoparticle solution was dialyzed
against ultra-pure water in order to remove unlinked FITC for 24 h
and filtered (pore size <220nm) in sterile and dark conditions. The
final product was obtained as an orange powder after freeze-drying.
The labeling efficiency was investigated by FTIR spectroscopy
(Perkin-Elmer 1600 series equipment, USA) and UV-vis spectro-
photometry (NanoDrop ND-1000; NanoDrop Technologies, USA).
Characterization of the CMCht/PAMAM Dendrimer Nanoparti-
cles: FTIR analyses were performed by means of preparing transpar-
ent potassium bromide pellets that contained the samples and using a
Perkin–Elmer spectroscope (Perkin–Elmer 1600 series equipment,
UK).
The morphology of the nanoparticles was investigated using atomic
force microscopy (AFM). The lyophilized CMCht/PAMAM dendri-
mer nanoparticles were dispersed in ultrapure water to obtain a
solution with a final concentration of 1mg mL"1, and then 20mL was
placed over a 9.9mm mica disc (Agar Scientific, England) and blow
dried with nitrogen gas for subsequent characterization. The samples
were analyzed using the Tapping Mode with a MultiMode AFM
connected to a NanoScope III controller, both from Veeco, USA, with
non-contact silicon nanoprobes (!300kHz) from Nanosensors,
Switzerland. All images were plane-fitted using the third degree-flatten
procedure included in the NanoScope software version 4.43r8. The
particle size distribution was determined with the same software. The
morphology and size of the particles was further analyzed by TEM
(Philips CM12, FEI Company, The Netherlands, equipped with a
MEGA VIEW-II DOCU camera and Image Software Analyzer SIS
NTDOCU). The nanoparticles were stained with 2% phosphotungstic
acid and placed on copper grids for further observation. The size of the
CMCht/PAMAM dendrimer nanoparticles was also measured in a
particle size analyzer (Zetasizer Nano ZS, Malvern Instruments, UK).
In-Vitro Cytotoxicity Screening of the CMCht/PAMAMDendrimer
Nanoparticles: A luminescent cell viability assay based on the ATP
quantification was performed by exposing RBMSCs to CMCht/
PAMAM dendrimer nanoparticles. Prior to the cell culture studies
CMCht, PAMAM-CTG1.5, andCMCht/PAMAMnanoparticles were
sterilized under an ethylene oxide gas atmosphere. RBMSCs were
isolated from the femora of 7week-old male Fischer 344/N rats (SLC
Inc. Japan), and expanded in T75 cm2 culture flasks in the presence of
MEM (Nacalai Tesque, Japan) with 15% FBS (JRH Biosciences,
USA) and 1%antibiotic-antimycotic (Nacalai Tesque, Japan) solution.
The animals were sacrificed by administrating an excess of anaesthesia,
in accordance to the Ethics Committee at the Tissue Engineering
Research Center (Amagasaki, Japan). After reaching confluency, the
cells (passage 1, P1) were released from the substratum and centrifuged
at 900 rpm for 5min. The supernatant was aspirated and cells
re-suspended with 10mL of complete culture medium. The cell
concentration was determined using an automatic cell counter (Cell
Counter Sysmex F-520, Japan). Viability of the RBMSCs was also
analyzed with a NucleoCounter (Chemometec, Denmark), using prior
seeding as described elsewhere. [56] RBMSCs were seeded (sub-
cultured) in each well of a 96-well TCPS plate at a cell density of 5' 103
cells mL"1. A solution of CMCht/PAMAMdendrimer nanoparticles at
a concentration of 10mg mL"1 was prepared in a complete culture
medium. Serial dilutions (1, 0.1, 0.01mg mL"1) were further prepared
using the complete culture medium. Possible changes in the osmolality
of the culture media were investigated using an automatic cryoscopic
osmometer (OSMOMAT O 30-D, Gonotec, Germany). After a
period of 24 h, the culture mediumwas changed by the respective serial
dilutions and the cells cultured under standard culture conditions for 1
and 3 d. A latex rubber extract was used as the positive control for
cellular death. Finally, the ATP content was measured by means of
performing a CellTiter-Glo luminescent cell viability assay, following
the protocol provided by the supplier (Promega Corporation, USA).
Luminescence was measured using an opaque-walled multi-well plate
in a microplate reader (Wallac ARVOsx 1420, Perkin-Elmer Life and
Analytical Sciences, USA). Results were analyzed for statistical
significance using a Student’s t-test with the JMP 5.0.1 software (SAS
Institute, Cary, N.C.).
Investigation of the Internalization Efficiency using SaOS-2 Cells
and RBMSCs under Fluorescence Microscopy and FACS Analysis: Human
osteoblast-like cells (SaOs-2 cells, ECACC, UK) were maintained in
T75 cm2 culture flasks, cultured with basic culture medium (MEM
supplemented with 10%FBS and 1%A/B) and passaged after reaching
confluence. A cell suspension was prepared and seeded on TCPS
coverslips (Sarstedt Inc., USA) in 24-well plates (1' 104 cells per well)
and cultured under standard culture conditions for 24 h. The
internalization of the CMCht/PAMAM dendrimer nanoparticles by
SaOs-2 cells was assessed after 3, 12, and 24 h, and 14 d. After each time
point cells on the TCPS coverslips were fixed with 4% formalin (Sigma,
Germany) and the nuclei stained with DAPI blue (100 ng mL"1,
Molecular Probes) to assess possible cell morphological changes.
Fluorescence was protected by using an antifade agent (ProLong
Antifade Kit, Invitrogen, USA), following the supplier procedure, and
cells were observed under the fluorescence microscope (AxioImager
Z1, Zeiss Inc., Germany).
RBMSCs were isolated from rats and expanded until reaching 80%
of confluency. The RBMSCs (P1) were trypsinized and transferred to a
6-well plate (1' 105 cells per well) and to TCPS coverslips in a 24-well
TCPS plate (2' 104 cells per well) for analysis under FACS and
fluorescence microscopy, respectively. For fluorescence microscopy,
RBMSCs were cultured in a MEM complete culture medium
containing 0.1mg mL"1 of FITC-labeled CMCht/PAMAM dendrimer
nanoparticles for a period of 12 h until 14 d. For FACS analysis,
RBMSCs were cultured in the presence of 0.01mg mL"1 of
FITC-labeled CMCht/PAMAM dendrimer nanoparticles. All experi-
ments were carried out in triplicate. The samples for fluorescence
microscopy were prepared as follows: each well was washed with 1mL
of PBS, and cells were fixed with 4% formalin (Nacalai Tesque, Japan)
for 10min at 4 8C followed by washing each well twice with PBS. After
that cells were incubated with 0.5mL of PBS that contained Texas
Red-X phalloidin (Molecular Probes, Invitrogen, USA) and Hoechst
33258 (Invitrogen, USA) for staining the actin filaments of the
cytoskeleton and nuclei of the cells, respectively. The protocols
provided by the supplier were followed with few modifications. The
permeabilization of cells with TritonX-100 was not carried out to avoid
any undesired effect on the integrity of the cells’ nuclei. TCPS
coverslips were washed once with PBS and fluorescence protected
using the ProLong antifade kit. The specimens were observed under a
fluorescence microscope (Olympus IX70, Olympus Co. Ltd, Japan).
FACS analysis was carried out as follows: each well of the 6-well plate
was washed with 2mL of PBS. PBS was then aspirated and cells were
released from the substratum as described above. Afterwards, 3.5mL
of MEM complete medium was added to each well and samples were
transferred to a 15mL Falcon. After centrifugation at 900 rpm for
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5min, cells were re-suspended in 0.5mL of complete culture medium
and passed through cell strainers [57]. Afterwards, 1mL of PI (Nacalai
Tesque, Japan) was added to each sample to determine the number of
live cells. After this step, cells were loaded into a FACSCalibur flow
cytometer (BD Biosciences Imunocytometry Systems, USA) and
analyzed with a minimum of 10 000 events counting. A Calibrite beads
three-color kit (BD CaliBRITE beads, USA) was used to adjust the
equipment instrument settings before samples were run on the flow
cytometer. Finally, the fluorescence-activated cell sorting (FACS) data
was treated using the FLOWJO software.
Investigation of the Effect of Colchicine and Apyrase on the
Internalization Efficiency of FITC-Labeled CMCht/PAMAM Dendri-
mer Nanoparticles by RBMSCs: A cell suspension of RBMSCs (P1) in
MEM complete culture medium was transferred to a 6-well
(1' 105 cells per well) plates and TCPS coverslips in a 24-well TCPS
plate (2' 104 cells per well) for analysis under FACS and fluores-
cence microscopy, respectively. Stock solutions of 10U mL"1 apyrase
(Nacalai Tesque, Japan) and 10' 10"6 M colchicine (Nacalai Tesque,
Japan) were prepared in a PBS solution. Cells were incubated under
standard culture conditions and after 24 h the culture medium was
replaced by a different complete culture medium that contained the
FITC-labeled CMCht/PAMAM dendrimer nanoparticles (0.01 and
0.1mg mL"1), and in the presence of 1' 10"6 M colchicine or
0.1UmL"1 apyrase or both, for a period of 12 h to 14 d. Controls for
internalization were performed by culturing RBMSCs in complete
culture medium and in the presence of both colchicine and apyrase. All
experiments were carried out in triplicate. After each time period,
specimens were prepared as described previously. The tendency of
FITC-labeled CMCht/PAMAM dendrimer nanoparticles to be inter-
nalized by RBMSCs was investigated by means of FACS analysis.
Investigation of the Dex Release from CMCht/PAMAMDendrimer
Nanoparticles: The amount of Dex released from the nanoparticles
was measured using an HPLC (ASI-Knauer, Germany) with an UV
detector set at 246 nm. The mobile phase consisted of acetonitrile/
acetate buffer (2' 10"3 M, pH 4.8 adjusted with glacial acetic acid)
(50 : 50, v/v) at flow rate of 1mL min"1. In brief, Dex release was
studied after dissolution of 10mg of Dex-loaded CMCht/PAMAM
dendrimer nanoparticles in 10mL of a PBS (pH 7.4, Sigma, USA)
solution in the absence or presence of 15% FBS. Sodium azide 0.01%
(w/v, Merck, Germany) was added to the buffer. The in-vitro release
studies were performed at 37 8C and 60 rpm for times that ranged from
1h to 7 d. At set time intervals, 1mL of sample was taken for analysis
and the same volume replaced by the respective buffer solution. Prior
analysis, samples were centrifuged at 2000 rpm for 10min. A solution
with sample/acetonitrile/acetate buffer (50:25:25 v/v) was prepared for
further analysis. A Eurospher 100 C-18 analytical column (ASI-
Knauer, Germany) was used. The retention time of Dex was 4min. A
calibration curve was obtained following the method described by Sun
et al. [58]. Results were expressed as an average% standard deviation,
n¼ 6.
Evaluation of Osteogenic Differentiation of the RBMSCs Cultured
in the Presence of CMCht/PAMAM Dendrimer Nanoparticles Loaded
with Dex, In Vitro: RBMSCs were isolated from F344/N rats and
expanded as described above. RBMSCs (P1) were cultured in a TCPS
24-well plate at a cell density of 2' 104 cells per well, and cultured in a
complete MEM for 24 h. After that time, the culture medium was
replaced by a different culture media, and RBMSCs were cultured for
times up to 14 d. The effect of the concentration of CMCht/PAMAM
dendrimer nanoparticles loaded with Dex on the RBMSCs osteo-
genic differentiation was investigated. Dex-loaded CMCht/PAMAM
dendrimer nanoparticles were dissolved in MEM supplemented with
0.28' 10"3 M ascorbic acid (Wako Pure Chemicals, Japan) and
10' 10"3 M b-glycerophosphate (Sigma, USA) at a final concentration
of 0.01 and 1mg mL"1. RBMSCS were also cultured in a complete
MEM, complete MEM that contained 1mg mL"1 of CMCht/PAMAM
dendrimer nanoparticles, and complete MEM that contained
10' 10"3 M b-glycerophosphate (negative controls). Complete MEM
supplemented with 10"8 M Dex, 0.28' 10"3 M ascorbic acid and
10' 10"3 M b-glycerophosphate was used as the positive control for
osteogenic differentiation. Culture media were changed every 2–3 d.
All experiments were carried out three times using a minimum of four
replicates per experimental condition.
Alizarin red S staining was performed to investigate possible
calcium deposition after 14 d of culturing. RBMSCs were washed
twice with PBS and fixed with 95% ethanol for 15min. The fixed cells
were then washed once with PBS and stained with 5mg mL"1 of
Alizarin red S in PBS for 5min at room temperature. A washing step
followed with ultra-pure water and the sample was mounted with
Crystal/Mount (BiomedaCorporation, USA) for observation under the
phase contrast microscope (Olympus CK40, Olympus Co. Ltd, Japan).
For the ALP staining, the cells were washed twice with PBS after
each culture period. Cells were fixed with 4% paraformaldehyde
(Nacalai Tesque, Japan) for 15min at 4 8C and then washed twice with
AMP buffer (56' 10"3 M of 2-amino-2 methylpropane-1,3-diol in
ultrapure water, pH 9.9). The cells were then soaked in a staining
solution of 0.5mg naphthol AS-MX phosphate and 0.5mg of fast red
violet LB salt per millilitre in AMP buffer. Cells were incubated for
10min at room temperature, washed with PBS, and mounted
(BiomedaCorporation, USA) for observation under the phase contrast
microscope.
DNA quantification was performed using Hoechst 33258 (Nacalai
Tesque, Japan), as previously described elsewhere [59].
ALP was measured to evaluate osteoblast differentiation. The
samples used for DNA quantification assay were used to determine the
ALP levels. Prior to analysis, the samples were centrifuged at
10 000 rpm for 1min at 4 8C. To each well of a 96-well plate was
added an aliquot of supernatant and p-nitrophenyl phosphate substrate
(ZYMED Laboratories, Invitrogen, USA). The plate was then
incubated in the dark for 30min at 37 8C. After the incubation period,
the reaction was stopped with 1M NaOH (Panreac). Standards were
prepared with p-nitrophenol (pNP). Triplicates were made for each
sample and standard. Absorbance was read at 405 nm (Wallac
ARVOsx 1420, Perkin–Elmer Life andAnalytical Sciences, USA), and
sample concentrations were read off from the standard graph. Enzyme
activity was expressed either as nmol of pNP released per well per
30min and normalized by DNA content.
The samples used for ALP activity were treated with a 20% formic
acid solution immediately after concluding the assay and stored at 4 8C
for 2–3 d. Samples were then centrifuged at 3000 rpm for 10min at 4 8C
and the supernatant passed through a Sephadex G-25 column (GE
healthcare, Sweden) for desalting. The filtered samples were
concentrated in a SPD SpeedVac attached to a UV Vacuum System
(Thermo Electron Corporation, USA), prior to osteocalcin quantifica-
tion. Finally, the osteocalcin content was determined by performing an
ELISA, and using a Rat Osteocalcin EIA kit (N8 BT-460, Biomedical
Technologies Inc., USA). The experimental procedure was carried out
following the instructions provided by the supplier. A 100 ng mL"1
standard solution of human osteocalcin was used to construct the
standard curve. Data was read off from the standard graph and
expressed as nanograms of deposited osteocalcin per microgram of
DNA.
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